[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100509757":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":32,"locations":37,"responsibleParty":54,"collaborators":11,"id":57,"slug":11,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":11,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":11,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":39,"whyStopped":11,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"University of Iowa","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"metformin","ACTIVE_COMPARATOR",null,[13],"Drug: Metformin Hydrochloride",{"label":15,"type":16,"description":11,"interventionNames":17},"placebo","PLACEBO_COMPARATOR",[18],"Other: placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Metformin Hydrochloride","12 weeks: 850mg metformin once daily for first 7 days then twice daily for the remaining 11 weeks.",[9],{"type":6,"name":15,"description":26,"armGroupLabels":27,"otherNames":11},"12 weeks: placebo tablet once daily for the first 7 days then twice daily for the remaining 11 weeks.",[15],[29],{"name":30,"affiliation":5,"role":31},"Anna Stanhewicz, PhD","PRINCIPAL_INVESTIGATOR",[33],{"name":30,"role":34,"phone":35,"phoneExt":11,"email":36},"CONTACT","3194671732","anna-stanhewicz@uiowa.edu",[38],{"facility":5,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Iowa City","Iowa","52242","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-91.53017,41.66113,{"lat":49,"lon":48},[52],{"name":30,"role":34,"phone":53,"phoneExt":11,"email":36},"319-467-1732",{"type":55,"investigatorFullName":30,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Assistant Professor","100509757",false,"NCT05917587","Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes","Inclusion Criteria:\n\n* ≥12 weeks and ≤5 years postpartum\n* history of GDM or healthy pregnancy\n\nExclusion Criteria:\n\n* prediabetes or diabetes (HbA1c ≥5.7%)\n* current tobacco use\n* cardiovascular or metabolic disease\n* cardiovascular or metabolic medication\n* history of hypertension during pregnancy\n* current pregnancy",true,"FEMALE","18 Years","45 Years",{"count":67,"type":68},30,"ESTIMATED","INTERVENTIONAL",[71],"EARLY_PHASE1","The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.",[74],"Gestational Diabetes",[76,77,78],"gestational diabetes","postpartum","vascular","2025-05-07",{"date":81,"type":82},"2025-05-13","ACTUAL",{"date":84,"type":82},"2024-09-11",{"date":86,"type":68},"2028-06-30",{"name":30,"class":6},1]